# US 2023/0274835 A1 · System and method for identifying prodromal parkinson's disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0274835 A1
- Document ID: US20230274835A1
- Status: Published application
- Kind: A1
- Application number: 18/109,810
- Filed: 2023-02-14
- Published: 2023-08-31
- Earliest claimed: 2022-02-14
- Applicants: Altoida, Inc.
- Inventors: Ioannis Tamanas; Maximilian Bugler; Robbert Harms
- Web page: https://patentgrep.com/patent/US20230274835A1

## CPC

- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B 40/20: Supervised data analysis
- G16H 10/20: for electronic clinical trials or questionnaires
- G16H 50/30: for calculating health indices; for individual health risk assessment
- G16H 50/70: for mining of medical data, e.g. analysing previous cases of other patients
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

A method of generating a digital biomarker signature for identification of a prodromal condition of a disease includes the steps of: obtaining a plurality of sets of digital biomarkers for preclinical Alzheimer's disease; selecting a subset of the plurality digital biomarkers; applying the subset of digital biomarkers to a group of subjects exhibiting a disease other than Alzheimer's; ranking the biomarkers of the subset on the basis of the commonality of each biomarker in said group of subjects; determining a digital biomarker signature indicative of said disease on the basis of the subset of the plurality of biomarkers and the ranking thereof. The other disease may be Parkinson's disease, and the subject of digital biomarkers may be deemed indicative of prodromal Parkinson's disease. An embodiment may use detection and prediction models for Alzheimer's disease to the identification of prodromal Parkinson's disease using explainable artificial intelligence.

## Claims

### Claim 1

A method of generating a digital biomarker signature for identification of a prodromal condition of a disease comprising the steps of:
obtaining a plurality of sets of digital biomarkers for preclinical Alzheimer's disease;
selecting a subset of the plurality of sets of biomarkers;
applying the subset of the plurality of sets digital biomarkers to a group of subjects exhibiting a disease other than Alzheimer's;
ranking the digital biomarkers of the subset on a basis of a commonality of each biomarker in said group of subjects; and
determining a digital biomarker signature indicative of said disease on the basis of the subset of the plurality of sets of digital of biomarkers and the ranking thereof.

### Claim 2 (depends on 1)

A method according to claim 1, wherein an other disease is Parkinson's disease and the subject of digital biomarkers is deemed indicative of prodromal Parkinson's disease.

### Claim 3 (depends on 1)

A method according to claim 1, including the step of determining which Alzheimer's disease biomarkers may also relate to prodromal Parkinson's disease and selecting the subset of biomarkers on the basis of said determined biomarkers.

### Claim 4 (depends on 3)

A method according to claim 3, wherein the subset of biomarkers is selected on a basis of biomarkers deemed predictive of both preclinical Alzheimer's disease and a biological mechanism of a-synucleinopathy in Prodromal-PD.

### Claim 5 (depends on 3)

A method according to claim 3, including the step of selecting biomarkers deemed predictive of both preclinical Alzheimer's disease in a group of patients at different stages of Alzheimer's disease.

### Claim 6 (depends on 3)

A method according to claim 3, including the step of testing the preclinical Alzheimer's disease biomarkers on a group of healthy patients and generating at least one digital biomarker signature for the group of healthy patients, the method including the step of determining the subset of biomarkers for prodromal Parkinson's disease on the basis of the digital biomarker signature of both the group of preclinical Alzheimer's disease patients and the group of healthy patients.

### Claim 7 (depends on 3)

A method according to claim 3, wherein the selection is based upon a generation of SHapley Additive exPlanations (SHAP).

### Claim 8 (depends on 3)

A method according to claim 3, wherein the subset of biomarkers is selected on a basis of measures of pre-motor symptoms and behavioural/cognitive decline.

### Claim 9 (depends on 3)

A method according to claim 3, wherein the subset of biomarkers is selected to include:
(i) a first contributing group of digital biomarker features indicative of brain network function and navigation micro-errors;
(ii) a second group of digital biomarker features relating to Augmented Reality global telemetry variance, representative of coarse-scale hand motion micro-movement; and
(iii) a third group of digital biomarker features comprising frequency magnitudes during object placement.

### Claim 10 (depends on 3)

A method according to claim 3, wherein the subset of the plurality of sets digital biomarkers is selected to take into account age and speed of motor function.

### Claim 11 (depends on 1)

A method according to claim 1, wherein the subset of biomarkers is selected to identify micro-errors and micro-movements detectable by Fourier analysis on accelerometer data that are not visible to a naked eye.

### Claim 12

Apparatus for generating a digital biomarker signature for identification of prodromal Parkinson's disease, the apparatus comprising a processing unit configured:
to obtain a plurality of sets of digital biomarkers for preclinical Alzheimer's disease;
to select a subset of the plurality of sets of digital biomarkers;
to apply the subset of digital biomarkers to a group of subjects exhibiting a disease other than Alzheimer's;
to rank the digital biomarkers of the subset on a basis of a commonality of each biomarker in said group of subjects; and
to determine a digital biomarker signature indicative of said disease on the basis of the subset of the plurality of sets of digital biomarkers and the ranking thereof.

### Claim 13 (depends on 12)

Apparatus according to claim 12, wherein an other disease is Parkinson's disease and the subject of digital biomarkers is deemed to be indicative of prodromal Parkinson's disease.

### Claim 14 (depends on 13)

Apparatus according to claim 13, wherein the processing unit is configured to determine which Alzheimer's disease biomarkers may also relate to prodromal Parkinson's disease and to select the subset of biomarkers on the basis of said determined biomarkers.

### Claim 15 (depends on 14)

Apparatus according to claim 14, wherein the processing unit is configured to select the subset of biomarkers on a basis of biomarkers deemed predictive of both preclinical Alzheimer's disease and a biological mechanism of a-synucleinopathy in Prodromal-PD.

### Claim 16 (depends on 14)

Apparatus according to claim 14, wherein the processing unit is configured to select biomarkers deemed predictive of both preclinical Alzheimer's disease in a group of patients at different stages of Alzheimer's disease.

### Claim 17 (depends on 14)

Apparatus according to claim 14, wherein the processing unit is configured to process preclinical Alzheimer's disease biomarkers from a group of healthy patients and to generate at least one digital biomarker signature for the group of healthy patients, and to determine the subset of biomarkers for prodromal Parkinson's disease on the basis of the digital biomarker signature of both the group of preclinical Alzheimer's disease patients and the group of healthy patients.

### Claim 18 (depends on 14)

Apparatus according to claim 14, wherein the processing unit is configured to make the selection based upon a generation of SHapley Additive exPlanations (SNAP).

### Claim 19 (depends on 14)

Apparatus according to claim 14, wherein the processing unit is configured to select the subset of biomarkers on a basis of measures of pre-motor symptoms and behavioural/cognitive decline.

### Claim 20 (depends on 14)

Apparatus according to claim 14, wherein the processing unit is configured to select the subset of biomarkers to include:
(i) a first contributing group of digital biomarker features indicative of brain network function and navigation micro-errors;
(ii) a second group of digital biomarker features relating to Augmented Reality global telemetry variance, representative of coarse-scale hand motion micro-movement; and
(iii) a third group of digital biomarker features comprising frequency magnitudes during object placement.

### Claim 21 (depends on 14)

Apparatus according to claim 14, wherein the processing unit is configured to select the subset of digital biomarkers to take into account age and speed of motor function.

### Claim 22 (depends on 13)

Apparatus according to claim 13, wherein the processing unit is configured to select the subset of biomarkers to identify micro-errors and micro-movements detectable by Fourier analysis on accelerometer data that are not visible to a naked eye.

### Claim 23

A method of treating a subject determined to have a degenerative disease, the method comprising:
(i) obtaining results of a method of generating a digital biomarker signature for identification of a prodromal condition of a disease, said method comprising the steps of:
obtaining a plurality of sets of digital biomarkers for preclinical Alzheimer's disease;
selecting a subset of the of sets of plurality digital biomarkers;
applying the subset of digital biomarkers to a group of subjects exhibiting a disease other than Alzheimer's;
ranking the biomarkers of the subset on a basis of a commonality of each biomarker in said group of subjects;
determining a digital biomarker signature indicative of said disease on the basis of the subset of the plurality of biomarkers and the ranking thereof; and
administering a treatment for reducing progression of the disease to the subject determined to have mild cognitive impairment due to the disease.

### Claim 24 (depends on 23)

A method according to claim 23, for treatment of a subject found to have at least one of: Prodromal Parkinson's Disease and Parkinson's Disease in a subject.

### Claim 25 (depends on 23)

A method according to claim 23, including administration of a treatment for reducing progression of Parkinson's Disease to a subject determined to have mild cognitive impairment due to Parkinson's Disease.

### Claim 26 (depends on 25)

A method according to claim 25, including the administration of at least one of: levodopa, dopamine agonists and monoamine oxidase-B inhibitors, benserazide, carbidopa.

### Claim 27 (depends on 12)

Apparatus according to claim 12, for use in a diagnosis of cognitive impairment due to at least one of: Prodromal Parkinson's Disease and Parkinson's Disease in a subject.

### Claim 28 (depends on 12)

Apparatus according to claim 12, for use in an administration of a treatment for reducing progression of Parkinson's Disease to a subject determined to have mild cognitive impairment due to Parkinson's Disease.
